Tag: Samsung Bioepis
Samsung Bioepis reaches settlement agreement for Eylea (Aflibercept) biosimilar in Europe...
This agreement enables Samsung Bioepis to launch SB15 in the United Kingdom (UK) from January 2026, in the rest of Europe from April 2026
Samsung Bioepis flags shifting PBM models and deepening price erosion in...
Q1 2026 Biosimilar Market Report tracks approvals, launches, pricing trends, and the potential impact of evolving PBM rebate frameworks on biosimilar uptake
“There are inconstancies across biosimilar classes right now”
Thomas Newcomer, VP, Head of US Market Access, Samsung Bioepis shares insightful perspectives on the US and Indian biosimilar markets
BioVoice eMagazine November & December 2023 | Issue 11 | Volume...
The Cover Story profiles India’s 10 Trailblazing MedTech Startups that hold a promising future ahead. Read interviews of Dr Sanjib Banerjee, COO, Veeda Clinical Research and Thomas Newcomer, VP, Samsung Bioepis. Startup Special features BramhAnsh Technologies, Bengaluru. Expert Insights by Raghavan Sampathkumar, ED, FSII and Navjot Singh,ED, Trivitron Healthcare.